Science Explorer Interactive view Map
Company · Hoboken · United States

Octapharma (United States)

octapharmausa.com/enROR OpenAlex
Research works
40
▲ 8% vs 2013–17
Citations
428
10.7 per fractional work
Top-10% rate
8.8%
record average 16.5%
Open access
33%
world 28%

Not ranked overall: Octapharma (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 1.54× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 6.20× its world share, 0 worksImmunology and Micro…Neuroscience: 2.02× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 2.23× its world share, 0 worksPharmacology, Toxico…Chemistry: 4.01× its world share, 0 worksChemistryMaterials Science: 0.83× its world share, 0 worksMaterials ScienceHealth Professions: 0.11× its world share, 0 worksHealth ProfessionsMedicine: 3.21× its world share, 5 worksMedicineNursing: 0.80× its world share, 0 worksNursingBusiness, Management and Accounting: 2.64× its world share, 1 worksBusiness, Management…Psychology: 0.43× its world share, 0 worksPsychology1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 6.2×. Every wedge is a field page.

Which keywords describe research at Octapharma (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Hemostasis, Prophylaxis, Gene Therapy, Factor VIII, Hemophilia, Thrombosis, Inflammation and Immune Thrombocytopenic Purpura.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 38 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 38 words, with their numbers
  1. Hemostasis7▲ 116×4 topics
  2. Inflammation4▲ 4.5×7 topics
  3. Prophylaxis4▲ 76×3 topics
  4. Gene Therapy4▲ 39×2 topics
  5. Factor VIII4▲ 573×1 topic
  6. Hemophilia4▲ 573×1 topic
  7. Thrombosis4▲ 42×2 topics
  8. Immune Thrombocytopenic Purpura3▲ 211×1 topic
  9. Platelets3▲ 130×1 topic
  10. Fibrinogen3▲ 245×1 topic
  11. Transglutaminases3▲ 245×1 topic
  12. Anemia3▲ 62×2 topics
  13. Alloimmunization2▲ 123×1 topic
  14. Blood Groups2▲ 123×1 topic
  15. Blood Transfusion2▲ 85×2 topics
  16. Depression2▲ 5.8×5 topics
  17. Epidemiology2◆ 1.01×12 topics
  18. Hemorrhage2▲ 55×2 topics
  19. Critical Care2▲ 17×2 topics
  20. Monoclonal Antibodies2▲ 27×3 topics
  21. Therapeutic Antibodies1▲ 28×2 topics
  22. Diagnosis1▲ 3.1×6 topics
  23. Stability1▲ 17×2 topics
  24. Risk Factors1▲ 2.8×4 topics
  25. Antioxidant1▲ 4.2×3 topics
  26. Apoptosis Induction1▲ 51×2 topics
  27. Genetic Mutations1▲ 5.2×2 topics
  28. Genetics1▲ 3.6×5 topics
  29. Treatment1▲ 2.1×9 topics
  30. Carbene Chemistry1▲ 95×1 topic
  31. Cardiac Surgery1▲ 32×1 topic
  32. Cyclopropanation1▲ 95×1 topic
  33. Garcinia Mangostana1▲ 350×1 topic
  34. Glycemic Control1▲ 18×2 topics
  35. Insulin Therapy1▲ 23×2 topics
  36. Protein Aggregation1▲ 32×2 topics
  37. St John's Wort1▲ 350×1 topic
  38. Tranexamic Acid1▲ 120×1 topic

Which research topics does Octapharma (United States) publish most on?

By volume in 2022–2025: Hemophilia Treatment and Research, Platelet Disorders and Treatments, FinTech, Crowdfunding, Digital Finance and Immunodeficiency and Autoimmune Disorders.

Hemophilia Treatment and…1Hemophilia Treatment and Research: 1 fractional worksPlatelet Disorders and T…1Platelet Disorders and Treatments: 1 fractional worksFinTech, Crowdfunding, D…0FinTech, Crowdfunding, Digital Finance: 0 fractional worksImmunodeficiency and Autoimmune Disorders: 0 fractional worksBlood transfusion and management: 0 fractional worksBlood Coagulation and Thrombosis Mechanisms: 0 fractional worksBlood properties and coagulation: 0 fractional worksMyeloproliferative Neoplasms: Diagnosis and Treatment: 0 fractional worksAtrial Fibrillation Management and Outcomes: 0 fractional worksTrauma, Hemostasis, Coagulopathy, Resuscitation: 0 fractional works
HematologyManagement Information SystemsImmunologyBiochemistry4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Hemophilia Treatment and Research Hematology 1 works
  2. 2 Platelet Disorders and Treatments Hematology 1 works
  3. 3 FinTech, Crowdfunding, Digital Finance Management Information Systems 0 works
  4. 4 Immunodeficiency and Autoimmune Disorders Immunology 0 works
  5. 5 Blood transfusion and management Biochemistry 0 works
  6. 6 Blood Coagulation and Thrombosis Mechanisms Hematology 0 works
  7. 7 Blood properties and coagulation Pulmonary and Respiratory Medicine 0 works
  8. 8 Myeloproliferative Neoplasms: Diagnosis and Treatment Genetics 0 works
  9. 9 Atrial Fibrillation Management and Outcomes Cardiology and Cardiovascular Medicine 0 works
  10. 10 Trauma, Hemostasis, Coagulopathy, Resuscitation Critical Care and Intensive Care Medicine 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available32.9%not open67.1%

World: 28% of research is openly available.

with international co-authors51.6%domestic only48.4%

World: 19% is written across borders.

How has Octapharma (United States)'s research output changed?

Output in 2018–2022 was 8% higher than in 2013–2017.

20002005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Hoboken

All research institutions in Hoboken

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.